| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 02/27/2003 | WO2003016486A2 Bio-synthetic photostimulators and methods of use |
| 02/27/2003 | WO2003016481A2 Novel human collagen proteins and polynucleotides encoding the same |
| 02/27/2003 | WO2003016480A2 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor |
| 02/27/2003 | WO2003016479A2 Excitatory glycine receptors and methods |
| 02/27/2003 | WO2003016478A2 G-protein coupled receptor polynucleotides and methods of use thereof |
| 02/27/2003 | WO2003016477A2 Insect or83b odorant receptor |
| 02/27/2003 | WO2003016473A2 Bovine leptin protein, antisense and antibody |
| 02/27/2003 | WO2003016472A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/27/2003 | WO2003016471A2 Periostin-based diagnostic assays |
| 02/27/2003 | WO2003016465A2 Cell cycle regulator protein |
| 02/27/2003 | WO2003016351A2 N - cam related compounds modulating cell groth |
| 02/27/2003 | WO2003016349A1 A method of producing glucagon-like peptide 1(glp-1)7-36 and an glp-1 analogue |
| 02/27/2003 | WO2003016348A2 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine |
| 02/27/2003 | WO2003016347A1 Method of preparing peptide fragment having cell death inhibitory activity |
| 02/27/2003 | WO2003016346A1 Ligands |
| 02/27/2003 | WO2003016345A1 Regulation of human regulator of g-protein signaling |
| 02/27/2003 | WO2003016344A2 Use of lung carcinoma antigen |
| 02/27/2003 | WO2003016343A2 USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS |
| 02/27/2003 | WO2003016342A2 Tumor antigens for prevention and/or treatment of cancer |
| 02/27/2003 | WO2003016341A2 Regulation of iron uptake |
| 02/27/2003 | WO2003016340A1 Derp1 and proderp1 allergen derivatives |
| 02/27/2003 | WO2003016339A1 A frog skin antibacterial peptide derivative |
| 02/27/2003 | WO2003016337A1 Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope |
| 02/27/2003 | WO2003016334A1 Methods for purification of an activated peg solution and for the synthesis of a modified hemoglobin solution |
| 02/27/2003 | WO2003016333A2 Virus coat protein/receptor chimeras and methods of use |
| 02/27/2003 | WO2003016330A2 Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors |
| 02/27/2003 | WO2003016329A2 Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
| 02/27/2003 | WO2003015814A1 New peptides and use thereof in therapeutic agents against feline fiv infection |
| 02/27/2003 | WO2003015812A2 Beta-amyloid-analogue-t-cell epitop vaccine |
| 02/27/2003 | WO2003015796A1 Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier |
| 02/27/2003 | WO2003015755A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | WO2003015714A2 Compositions and therapeutic methods for viral infection |
| 02/27/2003 | WO2003015712A2 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 02/27/2003 | WO2003015708A2 Composition and method for treating hiv infection |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015702A2 Epitopes of human immunodeficiency virus-1 |
| 02/27/2003 | WO2003015697A2 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | WO2003015692A2 Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| 02/27/2003 | WO2003015507A1 Development of transgenic model for interventions in neurodegenerative diseases |
| 02/27/2003 | WO2003015506A1 Propagation of human hepatoblastoma cell in non-human animals |
| 02/27/2003 | WO2003015505A2 An animal model exhibiting cancer, pulmonary emphysema and cardiomyopathy |
| 02/27/2003 | WO2003015500A2 Methods for the identification of inhibitors of phytochrome e expression or activity in plants |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003000894A9 Polynucleotide vaccine |
| 02/27/2003 | WO2002103000A3 Methods for modulating gap junctions |
| 02/27/2003 | WO2002102986A3 Novel human transporter proteins and polynucleotides encoding the same |
| 02/27/2003 | WO2002102977A9 Characterization of a membrane estrogen receptor |
| 02/27/2003 | WO2002102324A9 Anti-arthropod vector vaccines methods of selecting and uses thereof |
| 02/27/2003 | WO2002099037A3 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002095395A3 Benzophenone-linked crf and crf-like peptides for covalent labeling of corticotropin-releasing factor (crf) binding protein |
| 02/27/2003 | WO2002092763A3 Intron associated with myotonic dystrophy type 2 and methods of use |
| 02/27/2003 | WO2002092134A8 Lentiviral vectors encoding clotting factors for gene therapy |
| 02/27/2003 | WO2002090518A3 Differential regulation of t cell survival and proliferation |
| 02/27/2003 | WO2002086091A3 Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector |
| 02/27/2003 | WO2002081657A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 02/27/2003 | WO2002080851A3 Chimeric vaccines |
| 02/27/2003 | WO2002080845A3 Novel eps8 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002080844A3 Novel bgp compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002079407A8 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
| 02/27/2003 | WO2002078597A3 Oral absorbed drugs |
| 02/27/2003 | WO2002077167A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 02/27/2003 | WO2002074957A3 Stress-responsive activator of p300 (strap) protein |
| 02/27/2003 | WO2002074794A3 Compositions useful in gene therapy |
| 02/27/2003 | WO2002072846A3 Synthetic genes and bacterial plasmids devoid of cpg |
| 02/27/2003 | WO2002072814A3 Engineered baculoviruses and their use |
| 02/27/2003 | WO2002072763A3 Nucleic acids, proteins, and antibodies |
| 02/27/2003 | WO2002072017A3 Method of drug target validation |
| 02/27/2003 | WO2002070709A3 Molecules for disease detection and treatment |
| 02/27/2003 | WO2002070564A3 The guinea pig proteinase-activated receptor 4 and its activating peptide |
| 02/27/2003 | WO2002068651A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/27/2003 | WO2002067858A3 Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms |
| 02/27/2003 | WO2002066644A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/27/2003 | WO2002064736A3 Protein-protein interactions |
| 02/27/2003 | WO2002062203A3 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/27/2003 | WO2002061040A3 Gene delivery formulations and methods for treatment of ischemic conditions |
| 02/27/2003 | WO2002060951A3 Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| 02/27/2003 | WO2002059316A3 Human ion exchanger proteins and polynucleotides encoding the same |
| 02/27/2003 | WO2002058717A3 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 02/27/2003 | WO2002057422A3 Ternary biomolecule/polymer/surface-based immobilization systems |
| 02/27/2003 | WO2002055555A3 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002053016A3 Compounds and methods for the diagnosis and treatment of babesia infection |
| 02/27/2003 | WO2002051794A3 Connectable biochemical pincers and synthetic receptors for molecular organisation and manipulation of biomolecules |
| 02/27/2003 | WO2002048375A3 Purified active hcv ns2/3 protease |
| 02/27/2003 | WO2002048184A3 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test |
| 02/27/2003 | WO2002044336A3 Method of making a protein polymer and uses of the polymer |
| 02/27/2003 | WO2002042451A3 Aspergillus fumigatus cofilin |
| 02/27/2003 | WO2002041911A3 Use of fgf-19 for inhibiting angiogenesis |
| 02/27/2003 | WO2002036142A3 Compositions for inhibiting grb7 |
| 02/27/2003 | WO2002031156A3 Bvh-a2 and bvh-a3 antigens of group b streptococcus |
| 02/27/2003 | WO2002030973A3 The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof |
| 02/27/2003 | WO2002030471A3 A novel system for the evaluation of the activity and/or specificity of a viral component |
| 02/27/2003 | WO2002029047A3 Regulation of human gpcr-like protein |
| 02/27/2003 | WO2002020768A3 Caveolin peptides and their use as therapeutics |
| 02/27/2003 | WO2002020767A3 G-csf analog compositions and methods |
| 02/27/2003 | WO2002020761A3 Human vomeronasal receptor-4 |
| 02/27/2003 | WO2002018590A3 Identification of activated receptors and ion channels |
| 02/27/2003 | WO2002017711A3 Therapeutics and diagnostics based on a novel signal transduction system in platelets |
| 02/27/2003 | WO2002016621A3 Constitutive promoter from arabidopsis |
| 02/27/2003 | WO2002016548A8 Novel g protein-coupled receptor |